Watson, Mylan Slam FDA Over Generic Celebrex Decision
By Erica Teichert ( April 28, 2014, 3:46 PM EDT) -- Watson Laboratories Inc. and Mylan Pharmaceuticals Inc. hit the U.S. Food and Drug Administration with separate lawsuits Monday after the regulator determined another generic-drug maker still has exclusivity rights to market its version of Pfizer Inc.'s arthritis drug Celebrex....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.